吉利汽车(00175)发布公告，于2026年3月3日，该公司斥资6757.37万港元回购436.3万股。 ...

Core Viewpoint - The approval of the new indication for Pyrotinib (brand name: XuanYueNing) for first-line treatment of HR+/HER2- advanced breast cancer significantly enhances its clinical value and accessibility, supporting future sales growth for the company [1]. Company Summary - Four Seasons Pharmaceutical (00460) announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the new indication of Pyrotinib in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer [1]. - This marks the third approved indication for Pyrotinib in China, making it the first and only drug in the country to cover the entire treatment course for HR+/HER2- advanced breast cancer across first, second, and later lines [1]. Industry Summary - Breast cancer is the most commonly diagnosed malignant tumor among women globally, with new cases in China projected to rise from 322,200 in 2018 to 374,700 in 2024, and expected to reach 435,000 by 2032 [2]. - HR+/HER2- breast cancer is the most prevalent subtype in China, accounting for approximately 75% of total cases, with about 30% of these patients diagnosed with advanced breast cancer [2]. - The market for CDK4/6 inhibitors combined with endocrine therapy for HR+/HER2- advanced breast cancer in China is expected to reach RMB 13 billion by 2032 [2]. Clinical Research Summary - The approval of the new indication is based on data from the BRIGHT-3 study (NCT05257395), a randomized, double-blind Phase III clinical trial conducted at 58 centers in China [3]. - The study aimed to evaluate the efficacy and safety of Pyrotinib in combination with Letrozole or Anastrozole for first-line treatment of HR+/HER2- advanced breast cancer [3]. - Results indicated that the median progression-free survival (mPFS) for the Pyrotinib group has not yet been reached, while the control group reported mPFS of 18.43 months and 19.55 months, suggesting a durable efficacy advantage for Pyrotinib [3]. - The Pyrotinib regimen reduced the risk of disease progression or death by 47% compared to the placebo combined with endocrine therapy, with a notable 64% reduction in patients with liver metastases [3]. - The overall response rate (ORR) in the intention-to-treat population for the Pyrotinib group was 63.5%, significantly higher than the control group's 42.5% [3]. - Common adverse events associated with the Pyrotinib regimen were mostly grade 1-2 and manageable through supportive care or dose adjustments, indicating an overall controllable safety profile [3].

Group 1 - The core point of the article is that Geely Automobile announced a share buyback plan, intending to repurchase 4.363 million shares at a cost of HKD 67.5737 million [1] - The buyback will occur on March 3, 2026, with a price range of HKD 15.35 to HKD 15.80 per share [1]

Core Viewpoint - Geely Automobile (00175) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 4.363 million shares at a total cost of HKD 67.5737 million [1] - The buyback is scheduled to take place on March 3, 2026, suggesting a strategic long-term investment approach [1]

渣打集团(02888)发布公告，于2026年3月2日斥资1402.23万英镑回购80.9万股。 ...

本次新适应症的获批主要基于BRIGHT-3研究(NCT05257395)的数据结果。BRIGHT-3研究是一项在中国 58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗 HR+/HER2-晚期乳腺癌的有效性和安全性。此前，BRIGHT-3的研究成果在2025年欧洲肿瘤内科学会 (2025年ESMO)首次发表。结果显示，在疗效方面，吡洛西利组由研究者和独立评审委员会评估的mPFS 均暂未达到，对照组分别为18.43个月和19.55个月。mPFS尚未达到，提示吡洛西利组有更多患者仍未发 生疾病进展，反映出其持久的疗效优势。与安慰剂联合内分泌治疗相比，吡洛西利方案可降低47%的疾 病进展或死亡风险，且尤其在预后较差的肝转移患者中，疾病进展或死亡风险大幅降低64%，显示出其 在难治人群中的突出潜力。在意向治疗人群中，吡洛西利组的ORR达63.5%，显著优于对照组的42.5%; 安全性方面，吡洛西利联合方案常见不良事件(如腹泻、中性粒细胞减少等)多为1–2级，可通过支持治 疗或剂量调整得以有效管理，整体安全性可控。 乳腺癌是全球女性最常见被诊断出的恶性肿瘤，灼识咨询报告显示，中国 ...

智通财经APP讯，渣打集团(02888)发布公告，于2026年3月2日斥资1402.23万英镑回购80.9万股。 ...

编辑 杨娟娟 新京报贝壳财经讯（记者陈维城）3月3日，新京报贝壳财经记者从美团买药了解到，目前，美团买药平 台在北京覆盖的医保定点药店已超900家，较上线初期大幅增长233%。针对夜间购药难的痛点，平台联 合线上药店开启了 "小黄灯守护联盟"计划。目前，在支持线上医保买药的药店中，24小时营业的药店 占比高达45%，夜间（22点至次日8点）订单占比达20%。 在扩大药店覆盖面的同时，线上支持医保支付的药品种类也在持续扩容。目前，北京线上医保药品种类 已近8000个，较上线初期增长138%。据统计，美团买药北京线上医保购药的用户复购率已超过67%。 目前，从"为TA买药"绑定的用户数据来看，55岁及以上的用药人数占比为36%，降压药、感冒止咳药、 降糖药成为排名前三的高频用药需求。 校对 王心 ...

本次新适应症的获批主要基于BRIGHT-3研究(NCT05257395)的数据结果。BRIGHT-3研究是一项在中国 58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗 HR+/HER2-晚期乳腺癌的有效性和安全性。此前，BRIGHT-3的研究成果在二零二五年欧洲肿瘤内科学 会(「2025年ESMO」)首次发表。结果显示，在疗效方面，吡洛西利组由研究者和独立评审委员会评估 的mPFS均暂未达到，对照组分别为18.43个月和19.55个月。mPFS尚未达到，提示吡洛西利组有更多患 者仍未发生疾病进展，反映出其持久的疗效优势。与安慰剂联合内分泌治疗相比，吡洛西利方案可降低 47%的疾病进展或死亡风险，且尤其在预後较差的肝转移患者中，疾病进展或死亡风险大幅降低64%， 显示出其在难治人群中的突出潜力。在意向治疗人群中，吡洛西利组的ORR达63.5%，显著优于对照组 的42.5%；安全性方面，吡洛西利联合方案常见不良事件(如腹泻、中性粒细胞减少等)多为1–2级，可通 过支持治疗或剂量调整得以有效管理，整体安全性可控。 相关事件 四环医药(00460.HK)：轩悦宁®(吡洛西利片 ...

本次新适应症的获批主要基于BRIGHT-3研究(NCT05257395)的数据结果。BRIGHT-3研究是一项在中国 58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗 HR+/HER2-晚期乳腺癌的有效性和安全性。此前，BRIGHT-3的研究成果在2025年欧洲肿瘤内科学会 (2025年ESMO)首次发表。结果显示，在疗效方面，吡洛西利组由研究者和独立评审委员会评估的mPFS 均暂未达到，对照组分别为18.43个月和19.55个月。mPFS尚未达到，提示吡洛西利组有更多患者仍未发 生疾病进展，反映出其持久的疗效优势。与安慰剂联合内分泌治疗相比，吡洛西利方案可降低47%的疾 病进展或死亡风险，且尤其在预后较差的肝转移患者中，疾病进展或死亡风险大幅降低64%，显示出其 在难治人群中的突出潜力。在意向治疗人群中，吡洛西利组的ORR达63.5%，显著优于对照组的42.5%; 安全性方面，吡洛西利联合方案常见不良事件(如腹泻、中性粒细胞减少等)多为1–2级，可通过支持治 疗或剂量调整得以有效管理，整体安全性可控。 四环医药(00460)发布公告，集团旗下非全资附属公司轩竹生物科 ...